The market is most definitely starting to compare Snap's per-user metrics to rival social media platforms.
The Oracle of Omaha was slammed in a public letter from an advisor, but the missive misses the point.
The company's current valuation makes it tough to love, but even a modest pullback could bolster the bullish argument
Five Below partners with an esports network for in-store gaming as an alternate way to attract shoppers to its stores.
The OTT movement has been challenging for advertisers, who just want a way of simplifying and quantifying use of the medium.
Augmented and virtual reality have yet to live up to the hype, bolstering the case that they could take years to do so.
Shrinking profit margins from a new e-commerce initiative will be worth it if the retailer starts to do more with customer data.
Analysts are starting to change their minds, but they've not fully articulated how or why Juniper will be able to uproot Arista.
If Mark Tritton is going to reverse the struggling retailer's failing fortunes, he's going to need to repeat his successful Target strategy.
A new report from Coresight Research lays out the next growth opportunity in consumer packaged goods.
There are several good reasons that two consecutive quarters of improved personal computer purchases could become three, and then four, or more.
Despite efforts to combat the sale of fakes on its online-selling platforms, the matter could still evolve into a significant fiscal liability.
The pair of strange retailing bedfellows may be laying the groundwork for cross-merchandising -- or even an acquisition.
The world's biggest retailer has wisely figured out not every online venture is the right fit.
The Food and Drug Administration took a big step on Friday, warning consumers to stop vaping THC, and inadvertently subverting several companies' initiatives.
The streaming video receiver is now showing pop-up ads during commercials, with more rival receivers coming to the market.
The wearables outfit has earned respect, but it's not earned much actual money.
The company's flagship drug is finally getting enough traction to drive major margin improvements.
With a third “tissue agnostic” tumor treatment given the green light, oncology is now a genetics-based science
Smart investors would do well to remember what went wrong when judging future acquisitions